|
|
|
|
|
|
|
|
|||||
| Home Help Feedback Subscriptions Archive Search Table of Contents | |||||
Journal of Cell Science, Vol 110, Issue 22 2771-2779, Copyright © 1997 by Company of Biologists
JOURNAL ARTICLES |
F Aurade, CM Pfarr, C Lindon, A Garcia, M Primig, D Montarras and C Pinset
Groupe de Developpement Cellulaire, Institut Pasteur, Department of Molecular Biology, Paris, France.
The muscle regulatory factor, myf5, is involved in the establishment of skeletal muscle precursor cells. Little is known, however, about the control of the expression of the gene encoding this basic helix-loop-helix (bHLH) factor. We have addressed this question in the mouse myogenic cell line, C2, and in a derivative of this cell line where the myf5 gene is the only muscle-specific bHLH factor to be expressed at the myoblast stage. We present evidence that the synthetic glucocorticoid dexamethasone, and the pharmacological agent anisomycin, act synergistically to rapidly up-regulate the levels of myf5 transcript and protein. The glucocorticoid antagonist RU 486 abolishes this synergy, demonstrating the involvement of the glucocorticoid receptor. The expression of a dominant negative mutant of c-jun which interferes with the transactivating properties of all AP-1 family members also blocks the induction of myf5 by anisomycin and dexamethasone. An activator of protein kinase C (PKCs), 12-O-tetradecanoyl phorbol 13-acetate (TPA), abolishes the up-regulation of myf5 gene expression by dexamethasone and anisomycin, and its effect is counteracted by an inhibitor of PKCs, GF 109203X. These results point to the possible involvement of PKCs in the negative control of myf5. Evidence that both positive and negative regulation of myf5 transcripts, described here, does not require the fresh synthesis of transcription factors suggests that myf5 may behave like an immediate early gene.
This article has been cited by other articles:
|
|
 |
|
  S. Grandemange, P. Seyer, A. Carazo, P. Becuwe, L. Pessemesse, M. Busson, C. Marsac, P. Roger, F. Casas, G. Cabello, et al. Stimulation of Mitochondrial Activity by p43 Overexpression Induces Human Dermal Fibroblast Transformation Cancer Res., May 15, 2005; 65(10): 4282 - 4291. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. J. Andreucci, D. Grant, D. M. Cox, L. K. Tomc, R. Prywes, D. J. Goldhamer, N. Rodrigues, P.-A. Bedard, and J. C. McDermott Composition and Function of AP-1 Transcription Complexes during Muscle Cell Differentiation J. Biol. Chem., May 3, 2002; 277(19): 16426 - 16432. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Friday and G. Pavlath A calcineurin- and NFAT-dependent pathway regulates Myf5 gene expression in skeletal muscle reserve cells J. Cell Sci., January 1, 2001; 114(2): 303 - 310. [Abstract] [PDF]
|
|
|
|
 |
|
 P Daubas, S Tajbakhsh, J Hadchouel, M Primig, and M Buckingham Myf5 is a novel early axonal marker in the mouse brain and is subjected to post-transcriptional regulation in neurons Development, January 1, 2000; 127(2): 319 - 331. [Abstract] [PDF]
|
|
|
|
 |
|
 M. Kitzmann, G. Carnac, M. Vandromme, M. Primig, N. J.C. Lamb, and A. Fernandez The Muscle Regulatory Factors MyoD and Myf-5 Undergo Distinct Cell Cycle-specific Expression in Muscle Cells J. Cell Biol., September 21, 1998; 142(6): 1447 - 1459. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Carnac, M. Primig, M. Kitzmann, P. Chafey, D. Tuil, N. Lamb, and A. Fernandez RhoA GTPase and Serum Response Factor Control Selectively the Expression of MyoD without Affecting Myf5 in Mouse Myoblasts Mol. Biol. Cell, July 1, 1998; 9(7): 1891 - 1902. [Abstract] [Full Text]
|
|
|
|
|
|
C. Lindon, D. Montarras, and C. Pinset Cell Cycle-regulated Expression of the Muscle Determination Factor Myf5 in Proliferating Myoblasts J. Cell Biol., January 12, 1998; 140(1): 111 - 118. [Abstract] [Full Text] [PDF]
|
|
